CNR1 and schizophrenia: CB1R antagonists, on the other hand, have gone through clinical development and trials but given the development of adverse psychiatric side effects (particularly depression and anxiety), as well as their apparent lack of efficacy in other psychiatric conditions such as schizophrenia, it seems unlikely that this class of drug will be pursued as therapeutic option for psychiatric conditions.